

AMENDMENT

In the Claims

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-40 (Canceled)

41. (Previously presented) A fusion protein comprising an immunogenic polypeptide, wherein the immunogenic polypeptide consists of the amino acid sequence motif Xaa-Thr-Xaa-Val-Thr-Gly-Gly-Xaa-Ala-Ala-Arg-Thr-Thr-Xaa-Gly-Xaa-Xaa-Ser-Leu-Phe-Xaa-Xaa-Gly-Xaa-Ser-Gln-Xaa-Ile-Gln-Leu-Ile (SEQ ID NO:8).

42. (Currently amended) The ~~immunogenic polypeptide~~ fusion protein of claim 41 linked to a suitable carrier.

43. (Currently amended) The ~~immunogenic polypeptide~~ fusion protein of claim 42 linked to a disulfide/amide-forming agent.

44. (Currently amended) The ~~immunogenic polypeptide~~ fusion protein of claim 42 linked to a thio-ether-forming agent.

45-51. (Canceled)

52. (Currently amended) An immunogenic composition comprising a pharmaceutically acceptable carrier and the ~~immunogenic polypeptide~~ fusion protein of claim 41.

53. (Cancelled)

54. (Canceled)

55. (Currently amended) The ~~immunogenic polypeptide~~ fusion protein of claim 42, wherein the carrier is diphtheria toxoid.

56. (Previously presented) The immunogenic composition of claim 52, wherein the carrier is diphtheria toxoid.

57. (Canceled)